Table 1. Clinical, biological features and karyotype of t-AML patients.
| Pts1 | Age2/ | Primary 3 - | PC Tt4 | FAB5 | Karyotype at diagnosis of t-AML | FISH6 | p-AML | AML | Allog.9 | Survival> |
| Sex | Cancer3 - | Type7 | Tt8 | 12 month | ||||||
| t-1 | 71/F | Ovarian | Tax/SP/PSC833/Iressa | RAEB | 57,XXX,+1,+4,del(5)(q15;q33)×2,−7,+8,+9, | MLL WT | A | no | no | no |
| C. | +13,+14,−17,+18,+19,−20,+22,+mar [4] | |||||||||
| t-2 | 67/F | VLSL | Fluda/Chlorambucil | AML-M5 | 44, XX, 5q-, −7, −12, −14, −18,+ der(12?) | MLL WT | A | no | no | dead at |
| +mar [20] | diagnosis | |||||||||
| t-3 | 44/F | Breast C | Alk/AT II | AML-M0 | 46,XX,der(1)t(1;17)(p36;?),der(7) | MLL ND | U | yes | yes | yes |
| Lipo- | t(7;?)(p15;?),der(10)(7;10;17)(?;p11; | |||||||||
| sarcoma | q?21),der(17)(q11?),ins(17?) [11] | |||||||||
| t-4 | 45/F | Astrocy-, | RT/BCNU/Alk/ | AML-M0 | 45,XX,dup(2)(q22;q34),-3p21, | MLL WT | U | yes | no | no |
| toma | AT II, Autograft | t(5;13)(p15;q14),t(6;8)(p21;q24),+i(7q) | ||||||||
| + skin | ,der(7)t(7;15)(q10;q10),der(12) | |||||||||
| T NHL | t(12;17)(p13;q11),−15,−17 [18] | |||||||||
| t-5 | 72/M | Esophag. | 5FU/SP/RT/curie | RAEB | 45,XY,add(1)(q41),−5,−7, +mar [11]/ | MLL ND | A | no | no | no |
| C | 45,XY,add(1)q41,−5,−7, | |||||||||
| t(12;20?)(p12;q12),+mar [11] | ||||||||||
| t-6 | 44/M | Follicular | ATII/Alk/Oncovin | AML | 46,del(X)(q23),Y,der?(6),t(2;6)(q12; | MLL ND | A | no | no | no |
| NHL | Alk/AT II/TBI/ | q21),−7,del(18?)(q12),add(20)(q12) | ||||||||
| Alk Fluda | but uncertain conclusion at diagnosis | |||||||||
| t-7 | 73/M | Multiple | Alk/steroids/INF/ | AML + | 46–47,XY,−7,−8,+r+dm [20] | MLL ND | A | no | no | no |
| myeloma | AT II/BCNU | Myeloma | ||||||||
| t-8 | 72/M | Follicular | Alk/ATII/Fluda/ | AML-M5 | 47,XY,del(7)(q21q32),+13 [11] | MLL ND | A | yes | no | no |
| NHL | Chlorambucil, | |||||||||
| Rituximab/ | ||||||||||
| Spleen RT | ||||||||||
| t-9 | 69/M | Head and | RT | AML-M5 | 45,XY, −7 [12] | MLL WT | A | no | no | no |
| Neck C. | ||||||||||
| t-10 | 57/M | Bladder | RT/SP | MDS | 46,XY, [14]/46–47,XY,del(7q-) [5] | MLL ND | A | no | no | no |
| Cancer | WCP 7 | |||||||||
| t-11 | 62/M | Follicular | Alk/ATII/INF/ | AML-M5 | NA# | MLL ND | A | yes | no | no |
| NHL | MethylGAG | |||||||||
| Rituximab/skin RT | ||||||||||
| t-12 | 63/M | NSCLC | AT II/SP/RT | AML | 46 XY,t(8;21)(q22;q22) [1]/46 XY, | MLL ND | U | no | no | no |
| t(8;21)(q22;q22),del(7)(q11q34) [13] | ||||||||||
| t-13 | 38/F | Breast | Alk/RT/ | AML | 46,XX,add(1)(q 3?) [25] | MLL ND | U | yes | no | no |
| Cancer | ATII/RT/AM | |||||||||
| t-14 | 25/F | Endometre | Alk/AT II/SP, | AML-M4 | 47,XX, +8 [14] | MLL WT | U | yes | yes | yes |
| cancer | Actinomycine | |||||||||
| t-15 | 52/F | Breast | Alk/AT II/RT | biphenotypic | 48,XX,+8,t(9;22)(q34;q11),+17 [12] | MLL ND | U | yes | no | no |
| Cancer | AML-M4 | WCP 8 + | ||||||||
| WCP 17 | ||||||||||
| BCR-ABL fus | ||||||||||
| T | yes | no | yes | |||||||
| T | yes | no | yes | |||||||
| T | yes | no | yes | |||||||
| t-19 | 55/F | Breast | Alk/ATII/RT/HT/ | AML-M5 | 46,XX,t(9;11)(p21;q23) [21] | MLL ND | T | yes | no | no |
| Cancer | Tax | |||||||||
| t-20 | 61/F | Breast C. | Alk/AT II/RT/HT | AML-M5 | 46,XX,t(9;11)(p22;q23) [14] | MLL sep | T | yes | yes | no |
| t-21 | 60/F | NHL | Alk/AT II, Autograft | AML-M5 | 46,XX,t(9;11)(p22;q23) [12] | MLL sep | T | yes | no | no |
| t-22 | 19/M | Osteo- | Alk/AT II/SP | AML-M5 | 46,XY,t(9;11)(p21;q23) [8]/ | MLL sep | T | yes | no | yes |
| sarcoma | 46,XY,t(9;11)(p21;q23),+8 [10] | |||||||||
| t-23 | 22/F | HL | Alk/ATII/Bleo/ | AML-M5 | 46,XX,t(11;19)(q23;q13) [12] | MLL sep | T | yes | no | dead at |
| Oncov | diagnosis | |||||||||
| t-24 | 44/F | Ovarian | Tax/SP/AT II/ | biphenotypic AML | 46,XX, [2] | MLL sep | T | yes | no | no |
| cancer | Iressa | |||||||||
| t-25 | 64/F | Ovarian | Tax/SP/Iressa | MDS | 46,XX [17] | MLL WT | U | no | no | no |
| cancer | ||||||||||
| t-26 | 51/F | Anal + | RT, Alk/AT II/RT | AML | 46,XX [5] | MLL WT | U | yes | no | no |
| Breast C | ||||||||||
| t-27 | 47/F | Breast C. | Alk/AT II/RT/HT | AML-M2 | 46,XX [20] | MLL WT | U | yes | no | U |
| t-28 | 54/F | Breast C | Alk/AT II/RT | AML-M1 | 46,XX [16] | MLL WT | U | yes | yes | yes |
| t-29 | 71/M | Prostatic | RT | AML | 46,XY [20] | MLL WT | U | no | no | no |
| cancer. | ||||||||||
| t-30 | 67/M | Head and | AT II/SP/Bleo/RT | AML-M5 | 46,XY [21] | MLL WT | U | yes | no | no |
| Neck C. |
1 = patients. 2 = age at diagnosis of AML. 3 = Primary cancer; NHL: Follicular non hodgkin lymphoma, NSCLC: Non small cell lung cancer, VLSL: Villositary lymphocyte splenic lymphoma. 4 = Primary cancer treatment; Alk: alkylating agent, RT: radiotherapy, AT II: anti-topoisomerase II, AM: anti-metabolite, brachy: brachytherapy, Clo: Chlorambucyl, Tax: taxane, Fluda: fludarabine, SP: platinium, Bleo: bleomycin, HT: hormonotherapy, INF: interferon, Rit: Rituximab, RT: Radiotherapy, TBI: Total Body Irradiation, Oncov: Oncovin, A: alkylating-agent-inducing type, T: anti-topoisomerase-inducing type, U: undetermined. 5 = FAB classification: biph = biphenotypic. 6 = FISH column: MLL WT = MLL Wild Type, MLL R = MLL rearranged, ND = Not Done. 7 = Type of t-AML; A: alkylant induced, T anti-topoisomerase-induced. 8 = AML treatment. 9 = Allograft as treatment.
This patient had secondary MDS for several years before the leukemia, with transitory partial monosomy 7, that had disappeared a year later, two years later the t-AML appeared.